A J Scheen

Summary

Country: Belgium

Publications

  1. doi request reprint Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation)
    Andre J Scheen
    University of Liege, Division of Diabetes, Nutrition and Metabolic Disorders and Division of Clinical Pharmacology, Department of Medicine, CHU Sart Tilman B35, B 4000 Liege 1, Belgium
    Expert Opin Drug Metab Toxicol 7:1561-76. 2011
  2. doi request reprint DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials
    A J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman B35, University of Liege, Liege, Belgium
    Diabetes Metab 38:89-101. 2012
  3. ncbi request reprint Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease
    Andre J Scheen
    University of Liege, CHU Sart Tilman B35, Center for Interdisciplinary Research on Medicines CIRM, Division of Diabetes, Nutrition and Metabolic Disorders and Division of Clinical Pharmacology, Department of Medicine, B 4000 Liege 1, Belgium 32 4 3667238 32 4 3667068
    Expert Opin Drug Metab Toxicol 10:839-57. 2014
  4. pmc Pulsatile stress in middle-aged patients with type 1 or type 2 diabetes compared with nondiabetic control subjects
    Jean Christophe Philips
    University of Liege, Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, Centre Hospitalier Universitaire Sart Tilman, Liege, Belgium
    Diabetes Care 33:2424-9. 2010
  5. ncbi request reprint Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus
    Andre J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman B35, University of Liege, 4000, Liege 1, Belgium
    Clin Pharmacokinet 53:295-304. 2014
  6. ncbi request reprint Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor
    Andre J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders and Division of Clinical Pharmacology, Department of Medicine, CHU Sart Tilman B35, University of Liege, B 4000, Liege 1, Belgium
    Clin Pharmacokinet 53:213-25. 2014
  7. doi request reprint GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician?
    Andre J Scheen
    Service de Diabetologie, Nutrition et Maladies Metaboliques, Unite de Pharmacologie Clinique, Departement de Medecine, CHU Sart Tilman B35, Universite de Liege, 4000 Liege, Belgium Electronic address
    Ann Endocrinol (Paris) 74:515-22. 2013
  8. doi request reprint [Relationships between baroreflex gain and pulsatile stress in type 1 diabetic patients]
    A J Scheen
    Service de Diabetologie, Nutrition et Maladies Metaboliques, CHU Sart Tilman, Universite de Liege, Liege, Belgique
    Ann Cardiol Angeiol (Paris) 61:178-83. 2012
  9. doi request reprint Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease
    Andre J Scheen
    University of Liege, Division of Diabetes, Nutrition and Metabolic Disorders, Division of Clinical Pharmacology, Department of Medicine, CHU Sart Tilman B35, Liege, Belgium
    Expert Opin Drug Metab Toxicol 9:529-50. 2013
  10. doi request reprint Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes
    Andre J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman, University of Liege, Liege, Belgium
    Postgrad Med 125:7-20. 2013

Detail Information

Publications135 found, 100 shown here

  1. doi request reprint Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation)
    Andre J Scheen
    University of Liege, Division of Diabetes, Nutrition and Metabolic Disorders and Division of Clinical Pharmacology, Department of Medicine, CHU Sart Tilman B35, B 4000 Liege 1, Belgium
    Expert Opin Drug Metab Toxicol 7:1561-76. 2011
    ..The drug has a low potential for drug-drug interactions (DDIs) and no clinically relevant ones were reported so far...
  2. doi request reprint DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials
    A J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman B35, University of Liege, Liege, Belgium
    Diabetes Metab 38:89-101. 2012
    ..The role of DPP-4 inhibitors in the therapeutic armamentarium of type 2 diabetes is rapidly evolving as their potential strengths and weaknesses become better defined mainly through controlled clinical trials...
  3. ncbi request reprint Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease
    Andre J Scheen
    University of Liege, CHU Sart Tilman B35, Center for Interdisciplinary Research on Medicines CIRM, Division of Diabetes, Nutrition and Metabolic Disorders and Division of Clinical Pharmacology, Department of Medicine, B 4000 Liege 1, Belgium 32 4 3667238 32 4 3667068
    Expert Opin Drug Metab Toxicol 10:839-57. 2014
    ..However, the use of several antidiabetic agents may be a cause for concern in the case of hepatic impairment (HI)...
  4. pmc Pulsatile stress in middle-aged patients with type 1 or type 2 diabetes compared with nondiabetic control subjects
    Jean Christophe Philips
    University of Liege, Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, Centre Hospitalier Universitaire Sart Tilman, Liege, Belgium
    Diabetes Care 33:2424-9. 2010
    ..We compared pulse pressure during an active orthostatic test in middle-aged patients with type 1 diabetes and with type 2 diabetes and corresponding nondiabetic control subjects...
  5. ncbi request reprint Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus
    Andre J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman B35, University of Liege, 4000, Liege 1, Belgium
    Clin Pharmacokinet 53:295-304. 2014
    ....
  6. ncbi request reprint Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor
    Andre J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders and Division of Clinical Pharmacology, Department of Medicine, CHU Sart Tilman B35, University of Liege, B 4000, Liege 1, Belgium
    Clin Pharmacokinet 53:213-25. 2014
    ..Increased UGE resulted in proportional reductions in fasting plasma glucose and mean daily glucose concentrations...
  7. doi request reprint GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician?
    Andre J Scheen
    Service de Diabetologie, Nutrition et Maladies Metaboliques, Unite de Pharmacologie Clinique, Departement de Medecine, CHU Sart Tilman B35, Universite de Liege, 4000 Liege, Belgium Electronic address
    Ann Endocrinol (Paris) 74:515-22. 2013
    ..Physicians may guide the pharmacological choice based on clinical characteristics, therapeutic goals and patient's preference. ..
  8. doi request reprint [Relationships between baroreflex gain and pulsatile stress in type 1 diabetic patients]
    A J Scheen
    Service de Diabetologie, Nutrition et Maladies Metaboliques, CHU Sart Tilman, Universite de Liege, Liege, Belgique
    Ann Cardiol Angeiol (Paris) 61:178-83. 2012
    ..The aim of our work is to study the relationships between CAN (estimated by baroreflex gain calculation) and arterial stiffness (estimated by pulsatile stress) in type 1 diabetic patients...
  9. doi request reprint Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease
    Andre J Scheen
    University of Liege, Division of Diabetes, Nutrition and Metabolic Disorders, Division of Clinical Pharmacology, Department of Medicine, CHU Sart Tilman B35, Liege, Belgium
    Expert Opin Drug Metab Toxicol 9:529-50. 2013
    ..However, most oral antidiabetic agents have limitations in case of renal impairment (RI), either because they require a dose adjustment or because they are contraindicated for safety reasons...
  10. doi request reprint Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes
    Andre J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman, University of Liege, Liege, Belgium
    Postgrad Med 125:7-20. 2013
    ..If these trials confirm that a DPP-4 inhibitor can reduce the cardiovascular burden of T2DM, it would be major progress that would dramatically influence the management of the disease...
  11. doi request reprint Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis
    Andre Scheen
    CHU Sart Tilman, Liege, Belgium
    Expert Opin Drug Saf 12:545-57. 2013
    ..Such incretin-based therapies offer some advantages over other glucose-lowering agents, but might be associated with an increased risk of acute pancreatitis...
  12. doi request reprint Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes
    A J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders and Division of Clinical Pharmacology, Department of Medicine, CHU Sart Tilman B35, University of Liege, 4000 Liege, Belgium
    Diabetes Metab 39:179-90. 2013
    ....
  13. ncbi request reprint [Limited add-on value of oral glucose-lowering agents in type 1 diabetes]
    A J Scheen
    Universite de Liege, Belgique
    Rev Med Liege 68:16-21. 2013
    ....
  14. doi request reprint Cardiovascular effects of gliptins
    Andre J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman B35, University of Liege, B 4000 Liege 1, Belgium
    Nat Rev Cardiol 10:73-84. 2013
    ..Major prospective clinical trials with predefined cardiovascular outcomes and involving various DPP-4 inhibitors are now underway in patients with T2DM and a high-risk cardiovascular profile...
  15. doi request reprint Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation
    Andre J Scheen
    University of Liege, Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman, B 4000 Liege 1, Belgium
    Expert Opin Drug Metab Toxicol 9:363-77. 2013
    ..Linagliptin is the most recently launched gliptin, with a unique pharmacokinetic (PK) profile characterized by negligible renal excretion and is now also available as a fixed-dose combination (FDC) with metformin...
  16. doi request reprint Efficacy and safety of Jentadueto® (linagliptin plus metformin)
    Andre J Scheen
    University of Liege, Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman B35, B 4000 Liege 1, Belgium
    Expert Opin Drug Saf 12:275-89. 2013
    ..Linagliptin shares a similar pharmacodynamic (PD) profile with other gliptins, but has a unique pharmacokinetic (PK) profile characterized by negligible renal excretion...
  17. doi request reprint Outcomes and lessons from the PROactive study
    Andre J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders, and Division of Clinical Pharmacology, Department of Medicine, CHU Sart Tilman, University of Liege, Liege, Belgium
    Diabetes Res Clin Pract 98:175-86. 2012
    ....
  18. ncbi request reprint [Use of oral glucose-lowering agents in patients with renal impairment]
    A J Scheen
    Service de Diabetologie, Nutrition et Maladies métaboliques et Unité de Pharmacologie clinique, Departement de Medecine, Universite de Liege, CHU Sart Tilman 4000 Liege, Belgique
    Rev Med Suisse 8:1614-20. 2012
    ..Concerning new inhibitors of renal SGLT2 cotransporters, they have a reduced efficacy and their safety remains to be demonstrated in presence of CKD...
  19. ncbi request reprint [Role of environment in complex diseases: air pollution and food contaminants]
    A J Scheen
    Universite de Liege, Chef de Service, Service de Diabetologie, Nutrition et Maladies métaboliques et Unité de Pharmacologie clinique, CHU de Liege, Belgique
    Rev Med Liege 67:226-33. 2012
    ..The complex interrelationships between food and pollutants, on the one hand, and between gene and environmental pollutants, including the influence of epigenetics, on the other hand, deserve further careful studies...
  20. ncbi request reprint [Type 2 diabetes: journey in the heart of a complex disease]
    A J Scheen
    Universite de Liege, Service de Diabetologie, Nutrition et Maladies métaboliques et Unité de Pharmacologie clinique, CHU de Liege, Belgique
    Rev Med Liege 67:326-31. 2012
    ....
  21. ncbi request reprint [Epigenetics, interface between environment and genes: role in complex diseases]
    A J Scheen
    Universite de Liege, Chef de Service, Service de Diabetologie, Nutrition et Maladies métaboliques et Unité de Pharmacologie clinique, CHU de Liege, Belgique
    Rev Med Liege 67:250-7. 2012
    ..In contrast to genetic predisposition, which is irreversible, epigenetic changes are potentially reversible, thus giving targets not only for prevention, but possibly also for the treatment of certain complex diseases...
  22. ncbi request reprint [Hypertension and diabetes: about a common but complex association]
    A J Scheen
    Universite de Liege, Service de Diabetologie, Nutrition et Maladies métaboliques et Unité de Pharmacologie clinique, Departement de Medecine, CHU de Liege
    Rev Med Liege 67:133-8. 2012
    ....
  23. ncbi request reprint [Linagliptin (Trajenta): a selective DPP-4 inhibitor with limited renal elimination]
    A J Scheen
    Universite de Liege, Service de Diabetologie, Nutrition et Maladies Metaboliques, CHU de Liege, Belgique
    Rev Med Liege 67:91-7. 2012
    ..Because of these favourable properties, linagliptin may be used without dose adjustment (5 mg once a day) in patients with renal impairment, as well as in elderly people...
  24. doi request reprint Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: yes
    Andre J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders, University of Liege, Liege, Belgium
    Eur J Intern Med 23:126-31. 2012
    ....
  25. pmc Prevalence of the metabolic syndrome in Luxembourg according to the Joint Interim Statement definition estimated from the ORISCAV-LUX study
    Ala a Alkerwi
    Centre de Recherche Public Santé CRP Santé, Centre d Etudes en Santé, Grand Duchy of Luxembourg
    BMC Public Health 11:4. 2011
    ....
  26. ncbi request reprint Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide
    Andre J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders and Division of Clinical Pharmacology, Department of Medicine, CHU Sart Tilman, University of Liege, Liege, Belgium
    Clin Pharmacokinet 46:93-108. 2007
    ..Although no studies have been performed in patients with type 2 diabetes, the latter combination should be avoided in clinical practice...
  27. doi request reprint Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders
    Andre J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman B35, University of Liege, B 4000 Liege, Belgium
    Best Pract Res Clin Endocrinol Metab 23:103-16. 2009
    ..Ongoing studies should demonstrate whether improved metabolic disorders with CB1 receptor antagonists (rimonabant, taranabant, etc.) would translate into fewer cardiovascular complications among high-risk individuals...
  28. ncbi request reprint The endocannabinoid system: a promising target for the management of type 2 diabetes
    Andre J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders and Clinical Pharmacology Unit, CHU Sart Tilman, University of Liege, Liege, Belgium
    Curr Protein Pept Sci 10:56-74. 2009
    ..New trials are supposed to confirm the potential role of rimonabant (and other CB1 neutral antagonists or inverse agonists) in overweight/obese patients with type 2 diabetes and high risk cardiovascular disease...
  29. ncbi request reprint New therapeutic approaches in type 2 diabetes
    A J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman, University of Liege, Liege, Belgium
    Acta Clin Belg 63:402-7. 2008
    ....
  30. ncbi request reprint Medications in the kidney
    A J Scheen
    Service de Diabetologie, Nutrition et Maladies métaboliques et Unité de Pharmacologie clinique, Departement de Medecine, CHU Sart Tilman, Liege, Belgique
    Acta Clin Belg 63:76-80. 2008
    ..Appropriate drug selection and dosing in patients with CKD is imperative to avoid drug adverse events and to ensure optimal patient outcomes...
  31. ncbi request reprint Inhibitors of cannabinoid receptors and glucose metabolism
    Andre J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders, CHU Sart Tilman, University of Liege, Liege, Belgium
    Curr Opin Clin Nutr Metab Care 11:505-11. 2008
    ....
  32. doi request reprint CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant
    A J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders and Clinical Pharmacology Unit, CHU Sart Tilman, University of Liege, Liege, Belgium
    J Neuroendocrinol 20:139-46. 2008
    ..New trials are supposed to confirm the potential role of rimonabant in patients with abdominal adiposity, atherogenic dyslipidaemia and/or type-2 diabetes, i.e. at high cardiometabolic risk...
  33. ncbi request reprint Pharmacokinetic interactions with thiazolidinediones
    Andre J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders and Division of Clinical Pharmacology, Department of Medicine, CHU Sart Tilman, University of Liege, Liege, Belgium
    Clin Pharmacokinet 46:1-12. 2007
    ..Although some food components have also been shown to potentially interfere with drugs metabolised with the CYP system, no published study deals specifically with these possible CYP-mediated food-drug interactions with glitazones...
  34. ncbi request reprint [Evaluation of insulinosecretion and insulinosensitivity]
    Andre J Scheen
    Service de Diabetologie, Nutrition et Maladies Metaboliques, CHU Sart Tilman, Universite de Liege, Liege, Belgique
    Therapie 62:311-8. 2007
    ..Insulin secretion should ideally be measured according to the corresponding insulin sensitivity. Dynamic tests are generally more informative than static measurements in the fasting state...
  35. ncbi request reprint [Diabetes mellitus: from clinical knowledge to public health concern]
    Andre J Scheen
    Service de Diabetologie, Nutrition et Maladies Metaboliques, Departement de Medecine, CHU Sart Tilman, Liege, B 4000 Liege, Belgique
    J Soc Biol 201:133-40. 2007
    ..A multi-risk intervention is mandatory to improve the cardiovascular prognosis. The prevention of diabetes and its complications is a major public health objective...
  36. ncbi request reprint Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms
    A J Scheen
    Department of Medicine, Division of Diabetes, Nutrition and Metabolic Disorders, CHU Sart Tilman B35, B 4000 Liege 1, Belgium
    Diabetes Metab 30:498-505. 2004
    ..What might be the main mechanism in the overall protection effect of ACEIs or ARBs remains an open question...
  37. ncbi request reprint [Does a "therapeutic memory" exist in cardiovascular prevention?]
    A J Scheen
    Universite de Liege, Service de Diabetologie, Nutrition et Maladies Metaboliques, CHU Sart Tilman, B 4000 Liege I
    Rev Med Suisse 3:1864-6, 1868-9. 2007
    ..These intriguing results argue for a long-term memory of previous therapeutic interventions in cardiovascular prevention...
  38. ncbi request reprint Abnormal glucose metabolism in patients treated with antipsychotics
    A J Scheen
    Department of Medicine, Division of Diabetes, Nutrition and Metabolic Disorders and Division of Clinical Pharmacology, CHU Sart Tilman B35, University of Liege, 4000 Liege I, Belgium
    Diabetes Metab 33:169-75. 2007
    ..When prescribing an atypical antipsychotic, a commitment to careful baseline screening and follow-up monitoring is essential in order to mitigate the risk of developing diabetes and associated complications...
  39. ncbi request reprint Antidiabetic agents in subjects with mild dysglycaemia: prevention or early treatment of type 2 diabetes?
    A J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU de Sart Tilman B35, 4000 Liege I, Belgium
    Diabetes Metab 33:3-12. 2007
    ....
  40. doi request reprint Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17)
    A J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, University of Liege, B 4000 Liege, Belgium
    Diabet Med 26:1033-9. 2009
    ..placebo in patients with Type 2 diabetes treated with combined metformin-sulphonylurea therapy in the PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive)...
  41. doi request reprint Bariatric surgery in patients with type 2 diabetes: benefits, risks, indications and perspectives
    A J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman, University of Liege, Liege, Belgium
    Diabetes Metab 35:537-43. 2009
    ..Thus, bariatric surgery may be said to be progressing towards so-called 'metabolic surgery', which merits further evaluation in patients with T2DM within a multidisciplinary approach that involves both surgeons and endocrinologists...
  42. doi request reprint Pharmacokinetics of dipeptidylpeptidase-4 inhibitors
    A J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders and Division of Clinical Pharmacology, Department of Medicine, CHU Sart Tilman, University of Liege, Liege, Belgium
    Diabetes Obes Metab 12:648-58. 2010
    ....
  43. doi request reprint A review of gliptins in 2011
    Andre J Scheen
    University of Liege, Division of Diabetes, Nutrition and Metabolic Disorders, and Division of Clinical Pharmacology, Department of Medicine, CHU Sart Tilman B35, B 4000 Liege 1, Belgium
    Expert Opin Pharmacother 13:81-99. 2012
    ..Dipeptidylpeptidase-4 (DPP-4) inhibitors offer new options for the management of type 2 diabetes (T2DM)...
  44. ncbi request reprint [Statins in the management of dyslipidemias]
    Andre J Scheen
    Universite de Liege, Service de Diabetologie, Nutrition et Maladies métaboliques et Unité de Pharmacologie clinique, Departement de Medecine, CHU de Liege, 4000 Liege, Belgique
    Rev Prat 61:1120-6. 2011
    ..Tolerance and safety profile is rather good even if muscular and hepatic adverse events may occur. The prescription of statins should target high-risk individuals and both therapeutic inertia and drug non-compliance should be avoided...
  45. ncbi request reprint [Renal SGLT2 inhibitors, new agents for the management of type 2 diabetes]
    A J Scheen
    Service de Diabetologie, Nutrition et Maladies Metaboliques, Departement de Medecine, CHU Sart Tilman, Liege, Belgique
    Rev Med Suisse 7:1621-4, 1626-9. 2011
    ..Dapagliflozin should be the first medication of this new pharmacological class to be commercialized for the management of type 2 diabetes...
  46. doi request reprint Squatting test: a dynamic postural manoeuvre to study baroreflex sensitivity
    Andre J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Liege, University of Liege, Belgium
    Clin Auton Res 22:35-41. 2012
    ..Indeed, the shift from squatting to standing imposes a major orthostatic stress leading to rapid and large changes in arterial blood pressure (BP) and heart rate (HR) allowing precise baroreflex assessment...
  47. doi request reprint Cytochrome P450-mediated cardiovascular drug interactions
    Andre J Scheen
    University of Liege, Division of Diabetes, Nutrition and Metabolic Disorders, Division of Clinical Pharmacology, Department of Medicine, CHU Liege, Belgium
    Expert Opin Drug Metab Toxicol 7:1065-82. 2011
    ..Some of these may lead to serious adverse events and it is, therefore, essential that clinicians are aware of the important interactions that occur...
  48. ncbi request reprint [Therapeutic approaches to improve blood glucose control in a patient with type 2 diabetes on a metformin-sulfonylurea combination]
    A J Scheen
    Universite de Liege, Belgique
    Rev Med Liege 66:215-21. 2011
    ..We will provide the pro-contra arguments concerning each therapeutic alternative and describe the practical modalities of an appropriate management according to the patient's characteristics...
  49. doi request reprint Central nervous system: a conductor orchestrating metabolic regulations harmed by both hyperglycaemia and hypoglycaemia
    A J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman, University of Liege, Liege, Belgium
    Diabetes Metab 36:S31-8. 2010
    ..Functional imaging is of interest for exploring diabetes-associated cerebral abnormalities. Thus, the intimate relationship between the brain and diabetes is increasingly acknowledged in both research and clinical practice...
  50. doi request reprint Cardiovascular risk-benefit profile of sibutramine
    A J Scheen
    University of Liege, Department of Medicine, CHU Liege, Liege, Belgium
    Am J Cardiovasc Drugs 10:321-34. 2010
    ..In conclusion, concern still persists about the safety profile of sibutramine regarding cardiovascular outcomes, and the drug should not be prescribed for overweight/obese patients with a high cardiovascular risk profile...
  51. ncbi request reprint [Multirisk approach of the type 2 diabetic patient: controversies surrounding target values after the ACCORD trial]
    Andre J Scheen
    Service de Diabetologie, Nutrition et Maladies métaboliques et Unité de Pharmacologie clinique, Departement de Medecine, CHU Sart Tilman, 4000 Liege, Belgique
    Rev Med Suisse 6:1582-7. 2010
    ..These rather disappointing results should be interpreted to provide practical guidelines...
  52. doi request reprint Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
    Andre J Scheen
    University of Liege, Division of Diabetes, Nutrition and Metabolic Disorders and Clinical Pharmacology Unit, CHU Liege, Liege, Belgium
    Diabetes Metab Res Rev 26:540-9. 2010
    ....
  53. doi request reprint Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin
    Andre J Scheen
    University of Liege, CHU Sart Tilman, Division of Diabetes, Nutrition and Metabolic Disorders and Division of Clinical Pharmacology, Department of Medicine, Liege, Belgium
    Expert Opin Drug Metab Toxicol 6:1265-76. 2010
    ..Adequate blood glucose control is necessary to minimize complications. DPP IV inhibitors (sitagliptin, vildagliptin, saxagliptin) offer new options for combined pharmacological therapy...
  54. doi request reprint Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions
    Andre J Scheen
    Division of Clinical Pharmacology and Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman, University of Liege, Liege, Belgium
    Clin Pharmacokinet 49:573-88. 2010
    ....
  55. doi request reprint Metformin + saxagliptin for type 2 diabetes
    Andre J Scheen
    University of Liege, Division of Diabetes, Nutrition and Metabolic Disorders, and Division of Clinical Pharmacology, Department of Medicine, CHU Sart Tilman B35, B 4000 Liege 1, Belgium
    Expert Opin Pharmacother 13:139-46. 2012
    ..Dipeptidyl peptidase-4 (DPP-4) inhibitors, by promoting insulin secretion and reducing glucagon secretion in a glucose-dependent manner, offer new opportunities for oral therapy after failure of metformin...
  56. ncbi request reprint Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
    Andre J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders, CHU Sart Tilman, University of Liege, Liege, Belgium
    Lancet 368:1660-72. 2006
    ..The aim of the RIO-Diabetes trial was to assess the efficacy and safety of rimonabant in overweight or obese patients with type 2 diabetes that was inadequately controlled by metformin or sulphonylureas...
  57. ncbi request reprint [Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies]
    A J Scheen
    Universite de Liege, Service de Diabetologie, Nutrition et Maladies Metaboliques, CHU Sart Tilman, Liege, Belgique
    Rev Med Suisse 2:1916-23. 2006
    ..Almost half of the metabolic effects, including adiponectin increase, occur beyond weight loss, suggesting a direct peripheral effect of rimonabant...
  58. ncbi request reprint Current management strategies for coexisting diabetes mellitus and obesity
    Andre J Scheen
    Division of Diabetes, Department of Medicine, Nutrition and Metabolic Disorders, CHU Sart Tilman, Liege, Belgium
    Drugs 63:1165-84. 2003
    ..This objective justifies more aggressive weight reduction programmes, including very-low-calorie diets and bariatric surgery, but only within a multidisciplinary approach and long-term strategy...
  59. ncbi request reprint Treatment of type 2 diabetes
    Andre J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman, B 4000 Liege I, Belgium
    Acta Clin Belg 58:318-24. 2003
    ....
  60. ncbi request reprint Pathophysiology of type 2 diabetes
    A J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman, Liege, Belgium
    Acta Clin Belg 58:335-41. 2003
    ..These two paradigms constitute the framework for the study of the interplay between insulin resistance and beta-cell dysfunction in type 2 diabetes as well as between our obesogenic environment and diabetes risk in the next decade...
  61. ncbi request reprint Pathophysiology of insulin secretion
    A J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman B35, B 4000 Liege 1, Belgium
    Ann Endocrinol (Paris) 65:29-36. 2004
    ..The better understanding of the pathophysiology of the disease should lead to the development of new strategies to preserve beta-cell function in both type 1 and type 2 diabetes mellitus...
  62. ncbi request reprint Management of the metabolic syndrome
    A J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman, Liege, Belgium
    Minerva Endocrinol 29:31-45. 2004
    ..The growing prevalence and high-risk nature of MetS highlights the need to identify individuals with this condition and to treat them with an aggressive multitargeted approach...
  63. ncbi request reprint Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system
    Andre J Scheen
    Division of Diabetes, Department of Medicine, Nutrition and Metabolic Disorders, CHU Sart Tilman, Liege, Belgium
    Drugs 64:2537-65. 2004
    ..From a practical point of view, they may offer a new strategy to reduce the ongoing epidemic and burden of type 2 diabetes...
  64. ncbi request reprint Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials
    A J Scheen
    Department of Medicine, Division of Diabetes, Nutrition and Metabolic Disorders, CHU Sart Tilman B35, B 4000 Liege 1, Belgium
    Diabetes Metab 30:487-96. 2004
    ..Considering the pandemic of T2DM, such pharmacological approach deserves further attention among the strategies aiming at preventing T2DM...
  65. ncbi request reprint Drug interactions of clinical importance with antihyperglycaemic agents: an update
    Andre J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman, Liege, Belgium
    Drug Saf 28:601-31. 2005
    ..In addition, some case reports have evidenced potential drug-drug interactions with various antihyperglycaemic agents that are usually associated with a higher risk of hypoglycaemia...
  66. ncbi request reprint Diabetes mellitus in the elderly: insulin resistance and/or impaired insulin secretion?
    A J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman, University of Liege, Liege, Belgium
    Diabetes Metab 31:5S27-5S34. 2005
    ..Weight loss, especially reduction of abdominal adiposity, and increased physical activity may contribute to improve insulin sensitivity and glucose tolerance, and prevent the development of type 2 diabetes in elderly people...
  67. ncbi request reprint [Triple oral therapy in type 2 diabetes]
    A J Scheen
    Departement de Medecine, CHU Sart Tilman, 4000 Liege I, Belgique
    Rev Med Suisse 1:1942, 1944-6, 1948. 2005
    ..Recent clinical trials have shown both the efficacy and safety of this triple oral therapy. However, its precise place remains to be better specified in the overall management of type 2 diabetes...
  68. ncbi request reprint [Insulin detemir (Levemir)]
    A J Scheen
    Service de Diabetologie, Nutrition et Maladies Metaboliques, Departement de Medecine, CHU Sart Tilman, Liege
    Rev Med Liege 60:814-9. 2005
    ....
  69. ncbi request reprint Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?
    Andre J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman, Liege, Belgium
    Drugs 63:933-51. 2003
    ..However, the best dosage of acarbose for this specific indication remains to be specified, especially when all three important parameters, efficacy, tolerance and cost, are taken into consideration...
  70. ncbi request reprint New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat
    A J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders, Division of Clinical Pharmacology and Therapeutics, Department of Medicine, CHU Sart Tilman, Liege, Belgium
    Diabetes Metab 28:437-45. 2002
    ....
  71. ncbi request reprint [Diabetic neuropathy: epidemiologic and predictive data]
    A J Scheen
    Departement de Medecine, CHU Sart Tilman B35, Liege, Belgique
    Diabetes Metab 24:45-9. 1998
    ..Once neuropathy is diagnosed, the physician should provide specific advice to diabetic patients in order to prevent possible dramatic complications...
  72. ncbi request reprint Severe/extreme obesity: a medical disease requiring a surgical treatment?
    A J Scheen
    Service de Diabetologie, Nutrition et Maladies Metaboliques, CHU Sart Tilman, Liege, Belgique
    Acta Clin Belg 54:154-61. 1999
    ....
  73. ncbi request reprint Does the metabolic syndrome help to select patients requiring high statin dose?
    A J Scheen
    Department of Medicine, CHU Sart Tilman B35, B 4000 Liege, Belgium
    Lancet 368:893-4. 2006
  74. ncbi request reprint Antiobesity pharmacotherapy in the management of type 2 diabetes
    A J Scheen
    Division of Diabetes, Nutrition and Metabolic Diseases, Department of Medicine, University of Liege, CHU Sart Tilman, B 4000 Liege 1, Belgium
    Diabetes Metab Res Rev 16:114-24. 2000
    ..However, until now, results regarding efficacy and/or safety have been disappointing or preliminary in humans...
  75. ncbi request reprint [Advices for a better drug prescription]
    A J Scheen
    Universite de Liege, Belgique
    Rev Med Liege 61:488-93. 2006
    ....
  76. ncbi request reprint From obesity to diabetes: why, when and who?
    A J Scheen
    Departement de Medecine, CHU Sart Tilman, Liege, Belgique
    Acta Clin Belg 55:9-15. 2000
    ..The evolution from obesity to diabetes represents a continuum that progresses through different phases in which defects in both insulin action and insulin secretion play a critical interaction and must be looked at in concert...
  77. ncbi request reprint Thiazolidinediones and liver toxicity
    A J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman, Liege, Belgium
    Diabetes Metab 27:305-13. 2001
    ....
  78. ncbi request reprint Oral antidiabetic agents. A guide to selection
    A J Scheen
    Department of Medicine, CHU Sart Tilman, Liege, Belgium
    Drugs 55:225-36. 1998
    ....
  79. ncbi request reprint [Which indications for statins besides their cholesterol-lowering effect?]
    A J Scheen
    Service de Diabetologie, Nutrition et Maladies Metaboliques, Departement de Medecine, CHU Sart Tilman, 4000 Liege I, Belgique
    Rev Med Suisse 1:1954, 1956-9. 2005
    ..New prospective studies are mandatory before accepting such new potential indications of statins...
  80. ncbi request reprint Hepatotoxicity with thiazolidinediones: is it a class effect?
    A J Scheen
    Department of Medicine, CHU Sart Tilman, Liege, Belgium
    Drug Saf 24:873-88. 2001
    ....
  81. ncbi request reprint [Drug interactions: from theory to practice]
    A J Scheen
    Universite de Liege, Belgique
    Rev Med Liege 61:471-82. 2006
    ..Finally, we will illustrate these theoretical considerations with some examples of drug interactions, among the most dangerous and the most frequent in clinical practice...
  82. ncbi request reprint [The insulin sensitivity concept]
    A J Scheen
    Service de Diabetologie, Nutrition et Maladies Metaboliques, Departement de Medecine, CHU Sart Tilman, Liege, Belgique
    Diabetes Metab 27:193-200. 2001
    ....
  83. ncbi request reprint [Prevention of restenosis and of cardiac events after coronary angioplasty in diabetics]
    A Nyssen
    Universite de Liege, Service de Diabetologie, Nutrition et Maladies métaboliques et Unité de Pharmacologie clinique, Departement de Medecine, CHU Sart Tilman, 4000 Liege, Belgique
    Rev Med Suisse 5:1638-43. 2009
    ..Whenever possible, we will focus our attention on the results obtained in the diabetic population...
  84. doi request reprint Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18)
    A J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, University of Liege, Liege, Belgium
    Diabet Med 26:1242-9. 2009
    ..placebo in diabetic patients receiving metformin or sulphonylurea monotherapy at baseline in the PROspective pioglitAzone Clinical Trial in macroVascular Events (PROactive)...
  85. ncbi request reprint [Incidence of restenosis and cardiac events after coronary angioplasty in diabetic patients: reduction by systemic pharmacological approaches]
    A Nyssen
    Universite de Liege, Belgique
    Rev Med Liege 64:192-8. 2009
    ..Whenever possible, we will focus our attention on the results obtained in the diabetic population...
  86. ncbi request reprint [NAVIGATOR: A trial of prevention of cardiovascular complications and type 2 diabetes with valsartan and/or nateglinide]
    A J Scheen
    Universite de Liege, Belgique
    Rev Med Liege 65:217-23. 2010
    ..In contrast, valsartan reduced the incidence of type 2 diabetes by 14%, confirming the potential interest of the blockade of the renin-angiotensin system in this high-risk population...
  87. ncbi request reprint [Sugar: results of a Belgian observational study on the use of sitagliptin in patients with type 2 diabetes]
    A J Scheen
    Universite de Liege, Chef de Service, Service de Diabetologie, Nutrition et Maladies métaboliques et Unité de Pharmacologie clinique, CHU de Liege, Belgique
    Rev Med Liege 65:127-32. 2010
    ..After 3-6 months of follow up, more than 95% of patients still received sitagliptin, arguing for both the efficacy and the good tolerance of this new oral antidiabetic agent in clinical practice...
  88. ncbi request reprint [Fitness versus fatness: respective cardiometabolic impacts at different age ranges]
    N Esser
    Universite de Liege, Belgique
    Rev Med Liege 65:199-205. 2010
    ....
  89. ncbi request reprint [Metabolically obese normal-weight individuals and metabolically healthy, but obese, subjects]
    E Beck
    Universite de Liege, Service de Diabetologie, Nutrition et Maladies Metaboliques, Departement de Medecine, CHU Sart Tilman, 4000 Liege, Belgique
    Rev Med Suisse 5:1644-6, 1648-9. 2009
    ....
  90. ncbi request reprint [Info-congress. Prevention of type 2 diabetes in obese patients: first results with orlistat in the XENDOS study]
    A J Scheen
    Service de Diabetologie, Nutrition et Maladies métaboliques et de Médecine interne générale, Departement de Medecine, CHU Sart Tilman, Universite de Liege
    Rev Med Liege 57:617-21. 2002
    ..XENDOS is the first study demonstrating that an antiobesity agent, like orlistat, is able to reduce the progression to diabetes in obese subjects as compared with lifestyle changes alone...
  91. ncbi request reprint [Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes]
    A J Scheen
    Service de Diabetologie, Nutrition et Maladies Metaboliques, CHU Sart Tilman, Liege, Belgique
    Rev Med Liege 62:81-5. 2007
    ..Rimonabant is indicated in Europe as an adjunct to diet and exercise for the treatment of obese patients, or overweight patients with associated risk factor(s), such as type 2 diabetes or dyslipidaemia...
  92. ncbi request reprint [Insulin sensitizers]
    A J Scheen
    Universite de Liege, Service de Diabetologie, Nutrition et Maladies Metaboliques, Departement de Medecine
    Rev Med Liege 60:409-13. 2005
    ....
  93. ncbi request reprint [Clinical trial of the month. ADVANCE: improved survival and better vascular and renal outcomes with a fixed combination of perindopril and indapamide in patients with type 2 diabetes]
    A J Scheen
    Universite de Liege, Service de Diabetologie, Nutrition et Maladies métaboliques et Unité de Pharmacologie clinique, CHU Sart Tilman, Liege, Belgique
    Rev Med Liege 62:639-43. 2007
    ..There was no evidence that the effects of the study treatment differed by initial blood pressure level or concomitant use of other treatments at baseline...
  94. ncbi request reprint [ADOPT study: which first-line glucose-lowering oral medication in type 2 diabetes?]
    A J Scheen
    Universite de Liege, Belgique
    Rev Med Liege 62:48-52. 2007
    ..The potential risks and benefits, the profile of adverse events, and the costs of the three drugs should all be considered to help inform the choice of pharmacotherapy for patients with type 2 diabetes...
  95. ncbi request reprint [Medication of the month. Rosiglitazone (Avandia)]
    A J Scheen
    Service de Diabetologie, Nutrition et Maladies Metaboliques, Departement de Medecine, Universite de Liege
    Rev Med Liege 57:236-9. 2002
    ..As all glitazones, rosiglitazone moderately promotes weight gain. It can also induce some fluid retention which may reveal or aggravate heart failure in at risk patients...
  96. doi request reprint Pulse pressure and cardiovascular autonomic neuropathy according to duration of type 1 diabetes
    J C Philips
    Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman, Liege, Belgium
    Diabetes Metab Res Rev 25:442-51. 2009
    ..To evaluate changes in pulse pressure (PP) and markers of cardiovascular autonomic neuropathy (CAN) according to duration of type 1 diabetes mellitus (T1DM)...
  97. ncbi request reprint [Metabolically obese with normal weight individuals: an intriguing phenotype]
    E Beck
    Service de Diabetologie, Nutrition et Maladies métaboliques et Unité de Pharmacologie clinique, Departement de Medecine, CHU de Liege
    Rev Med Liege 64:16-24. 2009
    ..The present paper aims at better understanding the etiopathogenesis and pathophysiology of this particular phenotype, at evaluating its potential clinical consequences and at describing the main principles of its therapeutic management...
  98. ncbi request reprint [Postprandial hyperglycemia. II. Pharmacological approaches]
    A J Scheen
    Service de Diabetologie, Nutrition et Maladies Metaboliques, Departement de Medecine, CHU Sart Tilman
    Rev Med Liege 57:196-201. 2002
    ..Asp B28) or inhated insulin the action of which is faster than that of subcutaneous insulin. Post-prandial glucagon secretion can be inhibited by amylin. GLP-1 or insulin while other glucagon antagonists are currently in development...
  99. ncbi request reprint [How I explore ... the risk of a patient developing type 2 diabetes]
    A J Scheen
    Departement de Medecine, CHU Sart Tilman, 4000 Liege 1
    Rev Med Liege 57:113-5. 2002
    ..We summarize the most useful indices based on anamnesis, clinical examination and biological assays that can help to detect subjects at high risk of progression towards type 2 diabetes...
  100. ncbi request reprint [Info-Meeting. Pharmacologic prevention of the progression from impaired glucose tolerance to type 2 diabetes: favorable effects of metformin and acarbose]
    A J Scheen
    , , ,
    Rev Med Liege 56:727-30. 2001
    ..002). These results are, however, less marked than those obtained with lifestyle modifications including better dietary habits and increased physical exercise (-58% versus control group, p < 0.001)...